{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:51:43Z","timestamp":1790095903626,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.semnephrol.2014.04.008","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T10:09:46Z","timestamp":1397815786000},"page":"333-339","source":"Crossref","is-referenced-by-count":135,"title":["Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Ivana","family":"Lazich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2014.04.008_bib1","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.46.6415","article-title":"Analysis of factors causing hyperkalemia","volume":"46","author":"Takaichi","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s11096-013-9830-8","article-title":"Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia","volume":"35","author":"Kuijvenhoven","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(08)61212-X","article-title":"Renin-angiotensin blockade and kidney disease","volume":"372","author":"Sarafidis","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2014.04.008_bib8","first-page":"S81","article-title":"Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors","volume":"307","author":"Schlueter","year":"1994","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11255-004-6193-z","article-title":"Potassium metabolism in patients with chronic kidney disease (CKD), part I: patients not on dialysis (stages 3-4)","volume":"36","author":"Musso","year":"2004","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00350.x","article-title":"Hyperkalemia: an adaptive response in chronic renal insufficiency","volume":"62","author":"Gennari","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/MNH.0b013e328363ff76","article-title":"Regulation of potassium channel trafficking in the distal nephron","volume":"22","author":"Welling","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0891-6632(90)90057-C","article-title":"Hyperkalemia in diabetes mellitus","volume":"4","author":"Uribarri","year":"1990","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib13","doi-asserted-by":"crossref","unstructured":"Taal M, Chertow G, Marsden P, Skorecki K, Yu A, Brenner B. Adaptation to nephron loss and mechanisms of progression in chronic kidney disease. In: Brenner BM, Rector F (eds.): The kidney, 9th ed. Philadelphia: Saunders; 2011, pp. 893-915","DOI":"10.1016\/B978-1-4160-6193-9.10051-X"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semnephrol.2013.04.002","article-title":"Regulation of renal potassium secretion: molecular mechanisms","volume":"33","author":"Welling","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib15","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0026-0495(74)90032-8","article-title":"A mechanism for hyporeninemic hypoaldosteronism in chronic renal disease","volume":"23","author":"Oh","year":"1974","journal-title":"Metabolism"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1532-5415.2011.03818.x","article-title":"Metabolic complications in elderly adults with chronic kidney disease","volume":"60","author":"Drawz","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib19","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/archinternmed.2009.284","article-title":"Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy","volume":"169","author":"Weinberg","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.01150112","article-title":"Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic","volume":"7","author":"Sarafidis","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib22","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib25","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0272-6386(99)70181-2","article-title":"A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium","volume":"33","author":"Keilani","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib28","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"30","author":"Raebel","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrneph.2010.127","article-title":"Chronic kidney disease: the effect of CKD therapies on serum potassium levels","volume":"6","author":"Fink","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib31","first-page":"26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors","volume":"158","author":"Reardon","year":"1998","journal-title":"How much should we worry? Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib32","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib33","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib35","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jash.2010.09.006","article-title":"Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy","volume":"4","author":"Heshka","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib37","doi-asserted-by":"crossref","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","article-title":"Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study","volume":"6","author":"Boesby","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jch.12032","article-title":"Randomized study of antihypertensive efficacy and safety of combination aliskiren\/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus","volume":"15","author":"Bakris","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib42","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib43","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMc081065","article-title":"Telmisartan, ramipril, or both in patients at high risk of vascular events","volume":"359","author":"Buchner","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","article-title":"Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data","volume":"48","author":"MacKinnon","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib45","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib47","doi-asserted-by":"crossref","unstructured":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43 Suppl 1:S1-290.","DOI":"10.1053\/j.ajkd.2004.03.003"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib48","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.167586","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pds.1217","article-title":"Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers","volume":"16","author":"Raebel","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1345\/aph.1H520","article-title":"Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?","volume":"41","author":"Raebel","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11606-009-1228-x","article-title":"Diabetes and drug-associated hyperkalemia: effect of potassium monitoring","volume":"25","author":"Raebel","year":"2010","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib52","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/ndt\/gfg295","article-title":"Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone","volume":"18","author":"Cruz","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2710.2005.00694.x","article-title":"Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil","volume":"30","author":"Saito","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib54","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2215\/CJN.00120106","article-title":"Aldosterone antagonism in chronic kidney disease","volume":"1","author":"Ponda","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib55","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib58","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0002-9343(86)90934-4","article-title":"Implications of nonsteroidal anti-inflammatory drug therapy","volume":"80","author":"Zipser","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib60","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0002-9343(99)80017-5","article-title":"Heparin-induced aldosterone suppression and hyperkalemia","volume":"98","author":"Oster","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib61","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0196-0644(96)70012-4","article-title":"Hyperkalemia and digoxin toxicity in a patient with kidney failure","volume":"28","author":"Fenton","year":"1996","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000022089","article-title":"Trimethoprim-induced hyperkalemia: an analysis of reported cases","volume":"45","author":"Marinella","year":"1999","journal-title":"Gerontology"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1152\/ajplegacy.1939.127.3.430","article-title":"Factors affecting the toxicity of potassium","volume":"127","author":"Winkler","year":"1939","journal-title":"Am J Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/SMJ.0b013e31819e8978","article-title":"Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol","volume":"102","author":"McGowan","year":"2009","journal-title":"South Med J"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib66","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib67","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/ndt\/16.1.78","article-title":"Low-potassium and glucose-free dialysis maintains urea but enhances potassium removal","volume":"16","author":"Zehnder","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.008_bib68","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T13:25:17Z","timestamp":1565357117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929514000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0270929514000503"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2014.04.008","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}